Oragenics Inc. (OGEN) Dividend History

Company News

• Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial

  Oragenics, Inc. has submitted a clinical trial protocol for regulatory review to the Health and Disability Ethics Committee in New Zealand for its Phase II trial evaluating ONP-002, a proprietary neurosteroid therapy, for the treatment of mild traumatic brain injury or concussion.

  GlobeNewswire Inc.
• Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

  Oragenics provides an update on its drug candidate ONP-002 for treating concussion, including positive developments in stability, formulation, and clinical trial preparation. However, the company also discloses non-compliance with NYSE American listing standards.

  GlobeNewswire Inc.
• Oragenics delays 2023 Annual Meeting - Investing.com

  Oragenics, a biopharmaceutical company, has postponed its 2023 Annual Meeting of Shareholders, previously scheduled for August 26, 2024. The company stated that a new meeting date will be set and communicated in the future.

  Investing.com
• Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

  The device is intended for initial treatment in the acute setting The device is intended for initial treatment in the acute setting

  GlobeNewswire Inc.
• Oragenics, Inc. Announces Closing of Public Offering

  SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share.

  GlobeNewswire Inc.